Impact of preoperative [18F]FDG PET/CT vs. contrast-enhanced CT in the staging and survival of patients with clinical stage I and II non-small cell lung cancer : a 10-year follow-up study
© 2023. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine..
OBJECTIVES: To elucidate the impact of [18F]FDG positron emission tomography/computed tomography (PET/CT) vs. CT workup on staging and prognostic evaluation of clinical stage (c) I-II NSCLC.
METHODS: We retrospectively identified 659 cI-II NSCLC who underwent CT (267 patients) or preoperative CT followed by PET/CT (392 patients), followed by curative-intended complete resection in our hospital from January 2008 to December 2013. Differences were assessed between preoperative and postoperative stage. Five-year disease-free survival (DFS) and overall survival (OS) rates were calculated using the Kaplan-Meier approach and compared with log-rank test. Impact of preoperative PET/CT on survival was assessed by Cox regression analysis.
RESULTS: The study included 659 patients [mean age, 59.5 years ± 10.8 (standard deviation); 379 men]. The PET/CT group was superior over CT group in DFS [12.6 vs. 6.9 years, HR 0.67 (95% CI 0.53-0.84), p < 0.001] and OS [13.9 vs. 10.5 years, HR 0.64 (95% CI 0.50-0.81), p < 0.001]. In CT group, more patients thought to have cN0 migrated to pN1/2 disease as compared with PET/CT group [26.4% (66/250) vs. 19.2% (67/349), p < 0.001], resulting in more stage cI cases being upstaged to pII-IV [24.7% (49/198) vs. 16.1% (47/292), p = 0.02], yet this was not found in cII NSCLC [27.5% (19/69) vs. 27.0% (27/100), p = 0.94]. Cox regression analysis identified preoperative PET/CT as an independent prognostic factor of OS and DFS (p = 0.002, HR = 0.69, 95% CI 0.54-0.88; p = 0.004, HR = 0.72, 95% CI 0.58-0.90).
CONCLUSION: Addition of preoperative [18F]FDG PET/CT was associated with superior DFS and OS in resectable cI-II NSCLC, which may result from accurate staging and stage-appropriate therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Annals of nuclear medicine - 38(2024), 3 vom: 01. Feb., Seite 188-198 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lin, Jun-Tao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
[18F]FDG PET/CT |
|---|
| Anmerkungen: |
Date Completed 23.02.2024 Date Revised 23.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12149-023-01888-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366360957 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366360957 | ||
| 003 | DE-627 | ||
| 005 | 20240229144008.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12149-023-01888-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM366360957 | ||
| 035 | |a (NLM)38145431 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lin, Jun-Tao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of preoperative [18F]FDG PET/CT vs. contrast-enhanced CT in the staging and survival of patients with clinical stage I and II non-small cell lung cancer |b a 10-year follow-up study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2024 | ||
| 500 | |a Date Revised 23.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine. | ||
| 520 | |a OBJECTIVES: To elucidate the impact of [18F]FDG positron emission tomography/computed tomography (PET/CT) vs. CT workup on staging and prognostic evaluation of clinical stage (c) I-II NSCLC | ||
| 520 | |a METHODS: We retrospectively identified 659 cI-II NSCLC who underwent CT (267 patients) or preoperative CT followed by PET/CT (392 patients), followed by curative-intended complete resection in our hospital from January 2008 to December 2013. Differences were assessed between preoperative and postoperative stage. Five-year disease-free survival (DFS) and overall survival (OS) rates were calculated using the Kaplan-Meier approach and compared with log-rank test. Impact of preoperative PET/CT on survival was assessed by Cox regression analysis | ||
| 520 | |a RESULTS: The study included 659 patients [mean age, 59.5 years ± 10.8 (standard deviation); 379 men]. The PET/CT group was superior over CT group in DFS [12.6 vs. 6.9 years, HR 0.67 (95% CI 0.53-0.84), p < 0.001] and OS [13.9 vs. 10.5 years, HR 0.64 (95% CI 0.50-0.81), p < 0.001]. In CT group, more patients thought to have cN0 migrated to pN1/2 disease as compared with PET/CT group [26.4% (66/250) vs. 19.2% (67/349), p < 0.001], resulting in more stage cI cases being upstaged to pII-IV [24.7% (49/198) vs. 16.1% (47/292), p = 0.02], yet this was not found in cII NSCLC [27.5% (19/69) vs. 27.0% (27/100), p = 0.94]. Cox regression analysis identified preoperative PET/CT as an independent prognostic factor of OS and DFS (p = 0.002, HR = 0.69, 95% CI 0.54-0.88; p = 0.004, HR = 0.72, 95% CI 0.58-0.90) | ||
| 520 | |a CONCLUSION: Addition of preoperative [18F]FDG PET/CT was associated with superior DFS and OS in resectable cI-II NSCLC, which may result from accurate staging and stage-appropriate therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Computed tomography | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Stage migration | |
| 650 | 4 | |a [18F]FDG PET/CT | |
| 650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
| 650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 700 | 1 | |a Li, Xiang-Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Wen-Zhao |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Qing-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chun-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Xin-Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Kai-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Yi-Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Jia-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Yun-Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Fu-Gui |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Hong-Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Ri-Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Song |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Ben-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Si-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Yi-Long |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xue-Ning |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of nuclear medicine |d 1996 |g 38(2024), 3 vom: 01. Feb., Seite 188-198 |w (DE-627)NLM013015494 |x 1864-6433 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:3 |g day:01 |g month:02 |g pages:188-198 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12149-023-01888-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 3 |b 01 |c 02 |h 188-198 | ||